No Data
No Data
Express News | Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Organovo Announces the Issuance of Additional Shares in Conjunction With Warrant Exercises
Organovo Announces Issuance of Additional 3M Shares in Conjunction With Warrant Exercises
Eli Lilly and Co (LLY.US) acquired the FXR project and its main therapy FXR314 from Organovo, aimed at treating ulcerative colitis.
Currently, Organovo has obtained clinical trial approval from the USA FDA and is conducting its Phase 2 trial for its flagship therapy FXR314 for the treatment of ulcerative colitis (UC).
Sector Update: Health Care Stocks Higher Late Afternoon
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients